[VRUS] PHARMASSET INC. > 13.73 +0.31 ( +2.31%) Vol > 125484
Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company focuses on three product candidates: Clevudine, an oral pyrimidine nucleoside analog, for the treatment of HBV, which is entering the United States and European Phase III registration clinical trials, and is approved for HBV in South Korea and marketed by Bukwang Pharm. Co., Ltd. under the brand name Levovir; R7128, an oral pro-drug of PSI-6130 for the treatment of HCV, that is in a Phase 1 clinical trial through a strategic collaboration with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir for the treatment of HIV in combination with other approved HIV drugs that is in a Phase 2 clinical trial. It also engages in the discovery and development of additional antiviral therapeutics using nucleoside chemistry.
 |
